NoticeInformation only. Not medical advice. Nothing here is a recommendation to use any substance. Read full disclaimer
100 items
Investing.com Canada
DataMeds AI announced that subsidiary Corexa Health signed a commercial supply agreement covering six peptides. The company says Corexa Pharmacy plans to begin dispensing compounded prescriptions in November 2026; its release notes these drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
StreetInsider
DataMEDS AI announced that its pharmacy subsidiary Corexa Health signed a commercial supply agreement covering six peptides. The article reports that an FDA advisory committee recommended the peptides in July 2026, and the company says it intends to begin dispensing compounded prescriptions in November 2026.
The Batesville Daily Guard
DataMEDS AI announced that subsidiary Corexa Health entered a commercial supply agreement for six peptides. In the November 2, 2026 press release, the company says the peptides received FDA advisory committee recommendations and that Corexa Pharmacy plans to begin dispensing compounded prescriptions that month under an updated HHS enforcement discretion policy.
PR Newswire
Superpower announced a peptide-care program combining three compounds with blood testing and ongoing clinical support. The company says the compounded medications are not FDA-approved or authorized and that evidence of their safety and effectiveness in humans is limited.
The Indian Express
The Indian Express reports that US Health Secretary Robert F. Kennedy Jr. announced a draft policy easing compounding access to six experimental peptides under specified conditions. None has FDA approval, and an Indian endocrinologist warns that US enforcement discretion should not be mistaken for medical validation or regulatory approval in India.
VoxelMatters
VoxelMatters reports that PharmaTher is developing 3D-printed, colon-targeted KPV and BPC-157 tablets under an interim U.S. compounding pathway. A cited laboratory study delivered up to 75% of budesonide to a simulated colon using the delivery technology, but evidence for the proposed peptide treatment remains limited.
The Good Men Project
KFF Health News reports that an Oct. 14 proposal would let licensed pharmacies make and sell certain unapproved peptides despite FDA scientists’ concerns about inadequate clinical testing. The article challenges promotional claims that peptides are not drugs or are safe because they are natural.
Breaking News, Latest News and Videos
ABC News reports that FDA advisers narrowly recommended adding six peptides to a drug compounding list, despite unanimous opposition from FDA staff scientists. The recommendation is non-binding and requires FDA review and rulemaking; inclusion would not establish that the peptides are safe or effective.
Lee News Central
Lee News Central reports that FDA advisers will consider whether seven unapproved peptides should be allowed in certain compounded prescription drugs. The Pharmacy Compounding Advisory Committee meetings are scheduled for July 23 and 24, following restrictions the article says the FDA imposed on specific peptides in 2023 over potential safety risks.
Stocktwits
Stocktwits reports that Hims & Hers launched a consumer peptide campaign after its shares fell 7% last week. An FDA advisory committee is scheduled to review seven peptides for possible inclusion on the Section 503A Bulks List on July 23–24.
Demokratis.co.id
Demokratis.co.id reports that HHS announced an October 28, 2026 policy declining enforcement action against specified licensed providers compounding six unapproved peptides. HHS cited expanded patient access, while public health advocates and pharmacists raised concerns about limited evidence, safety, and production quality.
TrialSite News
TrialSite News reports that a coroner linked Richard Norton's death at 75 to experimental CJC-1295 and ipamorelin injections, with anaphylaxis implicated. Separately, the article reports that HHS announced a conditional enforcement-discretion policy for six peptides while FDA review continues; the action does not grant FDA approval.
Around Prague
Around Prague reports that an Australian coroner linked actor Richard Norton's death at 75 to an injection of unapproved CJC1295/ipamorelin. The coroner recommended that Australia's drug regulator review the peptides' benefits and risks and consider tighter restrictions.
Business Insider
Business Insider reports that HHS announced conditional enforcement discretion for pharmacies compounding BPC-157 and five other peptides. Human evidence remains scant; a randomized, placebo-controlled trial scheduled for summer 2027 will assess healing and safety in 20 shoulder-surgery patients.
Magzter
TIME reports that compounded GLP-1 weight-loss drugs remain available amid questions about regulatory enforcement and lower costs than branded options. The article cites a Gallup poll estimating that 5 million people in the U.S. use compounded GLP-1s.
PopTV Culture
PopTV Culture reports that Victorian Coroner David Ryan attributed actor Richard Norton’s death at 75 to anaphylaxis following CJC-1295 and ipamorelin injections, leading to cardiac arrest. The article says the peptides were not TGA-approved and that the coroner recommended a regulatory review.
The Regulatory Review
The Regulatory Review examines safety and access debates over compounded GLP-1 drugs after FDA declared tirzepatide and semaglutide shortages resolved. The article cites a nationwide recall of 22 vials of Apothecary Pharma’s compounded tirzepatide over sterility concerns, following an FDA warning about production deficiencies.
RadarOnline
RadarOnline reports that a coroner linked actor Richard Norton's death at 75 to complications involving unapproved CJC-1295 and Ipamorelin treatment. The coroner called on Australia's Therapeutic Goods Administration to review the peptides' risks and consider restricting their use to clinical trials and experiments.
RAPS
RAPS reports that HHS Secretary Robert Kennedy Jr.’s new enforcement discretion policy on compounding six unapproved peptides may face state resistance. Citing Politico, the article notes that states are not obligated to follow the policy, which was announced this week.
The National Law Review
The National Law Review headline reports that HHS announced limited enforcement discretion for compounding six peptides. The excerpt cuts off before the substantive article, leaving too little information to summarize the policy’s scope, conditions, or affected peptides.